Compare CLMT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLMT | STOK |
|---|---|---|
| Founded | 1916 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2006 | 2019 |
| Metric | CLMT | STOK |
|---|---|---|
| Price | $19.57 | $30.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $20.45 | ★ $31.00 |
| AVG Volume (30 Days) | 740.4K | ★ 946.2K |
| Earning Date | 11-07-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.68 |
| Revenue | ★ $4,048,000,000.00 | $205,632,000.00 |
| Revenue This Year | $0.16 | $430.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $45.22 |
| Revenue Growth | N/A | ★ 1128.17 |
| 52 Week Low | $7.68 | $5.35 |
| 52 Week High | $23.75 | $38.69 |
| Indicator | CLMT | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 58.81 | 59.84 |
| Support Level | $18.99 | $28.74 |
| Resistance Level | $19.80 | $31.44 |
| Average True Range (ATR) | 0.69 | 1.88 |
| MACD | 0.08 | 0.34 |
| Stochastic Oscillator | 92.25 | 92.30 |
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.